key: cord-1004816-yt90co4x
authors: Dubernet, Arthur; Larsen, Kevin; Masse, Laurie; Allyn, Jérôme; Foch, Emilie; Bruneau, Lea; Maillot, Adrien; Lagrange-Xelot, Marie; Thomas, Vincent; Jaffar-Bandjee, Marie-Christine; Gauzere, Loraine; Raffray, Loic; Borsu, Karine; Dibernardo, Servane; Renaud, Stéphane; André, Michel; Moreau, Diane; Jabot, Julien; Coolen-Allou, Nathalie; Allou, Nicolas
title: A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island
date: 2020-08-20
journal: J Glob Antimicrob Resist
DOI: 10.1016/j.jgar.2020.08.001
sha: b982c3ff9d8d9e3165d08333a8855710536f08d5
doc_id: 1004816
cord_uid: yt90co4x

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

VT, vincent.thomas@chu-reunion.fr MCJB, marie-christine.jaffarbandjee@chu-reunion.fr

LG, loraine.gauzere@chu-reunion.fr LR, loic.raffray@chu-reunion.fr KB, karine.borsu@chu-reunion.fr SD, servane.dibernardo@chu-reunion.fr SR, stephane.renaud@chu-reunion.fr

Reunion Island (845,000 inhabitants) is a French overseas department located in the Indian Ocean at a distance of 10,000 km from Paris. On 17 April 2020, 398 cases of COVID-19 had been reported in Reunion Island (first case detected on 11 March 2020) [1]. More than 70% of these cases were imported from Europe, which was an epicentre of the epidemic at the time.

The aim of this study was to evaluate the prognosis of COVID-19 patients in Reunion Island, with a particular focus on the medical management of patients with hypoxemic pneumonia.

The present study was approved by the Ethics Committee of the French Infectious Disease Society and was declared to the Commission nationale de l'informatique et des libertés (N°2206739). This retrospective observational study was conducted from 11 March to 17 April 2020 at the only hospital authorized to manage patients with COVID-19 in Reunion Island. Patients were systematically hospitalized in the following cases : pneumonia ; sepsis and comorbidities (age over 65 years, diabetes, heart disease, chronic respiratory disease, cancer, chronic kidney disease…). All patients with hypoxemic pneumonia due to COVID-19 J o u r n a l P r e -p r o o f were consecutively evaluated (i.e. pneumonia requiring oxygen to achieve oxyhemoglobin saturation > 94%).

In accordance with our protocol, all patients with hypoxemic pneumonia due to COVID-19 were treated with: (1) a 3 rd generation cephalosporin; (2) oral hydroxychloroquine for 10 days (400 mg twice on the first day, followed by 200mg twice a day for the next 9 days) in combination with azithromycin for 5 days (500 mg on the first day, followed by 250 mg daily for the next 4 days) in the absence of contraindications and if the symptoms lasted less than 10 days; and/or (3) corticosteroids, if more than 3L/min of oxygen was required 8 days after the onset of symptoms (1 mg/kg/day the first week, followed by 0.5 mg/kg/day the next 2 weeks). Patients were not treated by hydroxychloroquine/azithromycin if they didn't need oxygen therapy.

Keywords: COVID-19; SARS-CoV-2; hydroxychloroquine; azithromycin; corticosteroids.

Results were expressed as total numbers (percentages) for categorical variables and as medians [25 th -75 th percentiles] for continuous variables. Continuous variables were compared using the nonparametric Wilcoxon-Mann-Whitney-test. Categorical variables were compared using the Fisher's exact test. A P value < 0.05 was considered significant. Analyses were conducted using SPSS 15.0 (SPSS Inc©, Chicago, Il, USA). were treated in a medical ward.

Among the 13 hospitalized patients with hypoxemic pneumonia not treated by hydroxychloroquine/azithromycin : 2 were already treated by lopinavir/ritonavir, 7 had symptoms that lasted more than 10 days and 4 had contraindications.

Hydroxychloroquine/azithromycin treatment was stopped on day 4 in 1 patient due to QT prolongation.

Corticosteroid treatment was initiated in 12 patients (33.3%) 14 days [12-15] after the onset of symptoms. Of these, 6 were treated in a medical ward and 6 in ICU. A total of 5 patients received both hydroxychloroquine/azithromycin and corticosteroids.

In bivariate analysis, hydroxychloroquine/azithromycin treatment was associated with a lower rate of intensive care unit (ICU) admission (P=0.008) (Figure 1) . The factors predictive of ICU admission with P<0.05 are shown in Table 1 .

Ten of the 36 patients with hypoxemic pneumonia were admitted to ICU. Of these, 4 patients 

One patient under mechanical ventilation has been treated by tocilizumab. There were no deaths at follow-up (minimum 60 days). At the time of writing, 163 out of 164 hospitalized patients were discharged from hospital.

The evolution of patients was excellent overall, as not a single death due to COVID-19 was reported in Reunion Island. It should be noted, however, that the number of COVID-19 and the number of hypoxemia pneumonia cases were relatively low on the island. Several hypotheses can be put forward to explain our results. Our results may be due to the care bundle used for the management of patients with COVID-19 in Reunion Island. The main intervention was early treatment with hydroxychloroquine/azithromycin. Indeed, following bivariate analysis, hydroxychloroquine/azithromycin treatment was associated with a lower rate of ICU admission (P=0.008). Some studies suggest that this drug combination is associated with viral load decrease and improved prognosis when administered early [2, 3] . It should be noted, however, that the hydroxychloroquine/azithromycin treatment was not associated with better outcome in some retrospective studies [4] . Likewise, the administration of corticosteroids to patients with no improvement 8 days after the onset of symptoms may have contributed to the favourable outcome of patients with COVID-19 (none of the 6 patients treated with corticosteroids were hospitalized in ICU). One study has found corticosteroid treatment to be associated with decreased mortality in patients with hypoxemic pneumonia due to COVID-19 [5] .

This study has many limitations. This was a retrospective study with a relatively small number of patients, which made it impossible to perform multivariate analyses.

Despite the risk profile of COVID-19 patients with severe hypoxemic pneumonia, the mortality rate of the disease in Reunion Island was 0%. This may be due to the care bundle J o u r n a l P r e -p r o o f used in our hospital (early hospitalisation, treatment with hydroxychloroquine/azithromycin and/or corticosteroids, non-invasive respiratory support, etc.).

The present observational study was approved by the Ethics Committee of the French Society of Pulmonary Medicine and was declared to the Commission nationale de l'informatique et des libertés (French Data Protection Agency or CNIL MR004). Written and verbally informed consent was obtained from all the patients.

The dataset used in the current study are available from the corresponding author on reasonable request.

None declared.

This work was internally funded.

Drs. Arthur Dubernet, Kevin Larsen, Nathalie Coolen-Allou and Nicolas Allou had full access to all the study data and take responsibility for the completeness of the data and the accuracy of the analysis. 

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

COVID-19 patients with at least a six-day follow up: A pilot observational study

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report